What does a biotech reporter do with a press release that says your company is “excited to announce” a “positive” result and gives no numbers? At Endpoints News, the answer is usually nothing. The release goes into the same folder as the other forty that arrived before lunch, and the reporter moves on to the company that sent the effect size, the patient count and the p-value in the first paragraph.

That gap between the pitch that gets ignored and the pitch that gets a call back is the whole game when you are working out how to get featured in Endpoints News. This guide covers what the publication covers, why most pitches fail, a simple test we use before anything goes out and the mechanics of reaching the right reporter at the right moment.

What Endpoints News covers, and who reads it

Scientist in safety glasses using a pipette at a lab bench, the early research Endpoints tracks

Endpoints News was founded in 2016 by John Carroll and Arsalan Arif, who bootstrapped it with no outside money. In 2023 the Financial Times bought a majority stake, and the founders stayed on to run it. Its own media kit claims more than 256,000 daily email subscribers and more than 700,000 unique monthly visitors, and says it is read inside every one of the top 50 pharmaceutical companies.

Those readers are not casual. They are R&D heads, business development teams, biotech CEOs, venture investors, bankers and analysts. They open the morning email to find out which trial read out, which deal closed, who raised money, who got cut and which regulator decision moved a stock. They want the fact and the reason it matters, fast.

That audience shapes everything Endpoints publishes. The stories that run are about clinical data, FDA decisions, licensing and M&A deals, financings, layoffs and restructurings, executive moves and the strategy behind all of it. The tone is direct and sometimes sharp, and weak data gets called weak. Anyone researching how to get featured in Endpoints News should read a week of the morning email first to get a feel for it.

If your news would interest a biotech investor or a pharma BD team, Endpoints is a fit. If it would mostly interest patients or the general public, a consumer health outlet is a better first target.

Why most biotech pitches to Endpoints die in the inbox

The most common failure is hiding the number. Companies with soft data write around it. They say a drug “showed a trend toward” an effect, or that results were “encouraging,” and they leave the primary endpoint out of the headline. Endpoints reporters read clinical data all day. When a release buries the topline figure, they assume the figure is bad, and they are often right.

A related failure is the overclaim. Calling a Phase 1 safety study “a breakthrough” or a preclinical mouse result “a potential cure” costs you credibility with a reader who knows how often early results fail to translate. Endpoints readers have watched hundreds of promising programs die in later trials. Language that ignores that history tells the reporter you either do not know it or hope they do not. Describe what you found in the terms a scientist would use, and let the reporter decide how big it is.

The second failure is the context-free financing. A $40 million Series A is real news to the company that raised it. To a reporter who saw four rounds that size this week, it is a line in a roundup at best. What earns more is the story around the money: why these investors, why this target, why now, and what the company will prove with the cash before it needs more.

The third failure is the generic blast. A pitch sent to every biotech reporter in the same minute, with no sign the sender has read anything Endpoints has published, reads as spam. It does not matter how strong the news is if the email looks like it was written for no one.

The fourth failure is timing. Medical conference weeks, earnings season and the days around a major FDA calendar are crowded. A modest story pitched into that noise disappears.

The Readout Rule: what makes a story Endpoints-ready

Laptop showing graphs beside printed data analysis, the numbers a reporter checks before writing

We run every biotech pitch through what we call the Readout Rule before it goes anywhere near a trade reporter. It has four parts, and the pitch must answer all four in its first three sentences.

The first part is the number. Whatever the news is, there is a figure at the heart of it. For a trial, that is the primary endpoint result, the patient count and the comparator. For a deal, it is the upfront payment, the milestones and the royalty range. For a financing, it is the amount, the lead investor and the runway it buys. If you cannot state the number, you do not have a story yet.

The second part is the comparison. A number means little alone. A 40% response rate is impressive in one tumor type and disappointing in another. Tell the reporter what the result compares to: the standard of care, a rival’s recent data, the company’s own earlier trial, the typical deal size in that modality.

The third part is the consequence. What happens next because of this news? A pivotal trial starts. A partner opts in. A program gets shelved. A rival now has to respond. Endpoints readers care about what the news changes in the market, so the pitch should say it in one clear sentence.

The fourth part is the person. Offer a named executive who can talk on the record, with a time window. A chief medical officer who will walk through the subgroup data is worth more to a reporter than any quote you could write for a release.

Here is the difference in practice. A pitch that fails the rule reads: “We are pleased to share encouraging Phase 2 results for our lead candidate in solid tumors.” A pitch that passes reads: “Our Phase 2 trial in 64 patients with second-line gastric cancer hit its primary endpoint, with a 38% overall response rate against roughly 15% for the current standard. We plan to start a pivotal study in the first half of next year, and our CMO can walk you through the subgroup data today or tomorrow.” The second version gives the reporter a story. The first gives them homework.

How to find the right Endpoints reporter

Endpoints has reporters and editors across the US, Europe and Asia, and they tend to follow specific beats: certain therapeutic areas, regulators, deals, manufacturing or the biotech funding market. The fastest way to find yours is to read a few weeks of coverage and note who wrote about your competitors, your modality and your disease area.

Check the bylines on stories about the companies you would most like to be compared with. If a reporter covered a rival’s Phase 1 data last month, they will understand your Phase 2 data faster than anyone else in the newsroom. A short line that shows you read that piece (“you covered X’s dose escalation data in March; our results answer the durability question you raised”) tells them the pitch was written for them.

Keep the email short. A subject line that states the news with the number. Three sentences that pass the Readout Rule. A link to the release or data deck, not an attachment. Your spokesperson’s availability. Your direct phone number. That is enough.

Do not send the same pitch to five Endpoints reporters at once. Pick one. If you get no reply within a day or two and the news is still fresh, a single follow-up with one new detail is fine. A third email is not.

Timing, exclusives and embargoes

For market-moving news, timing is often set for you. Public companies release data and deals on a schedule tied to disclosure rules, often before the market opens. In those cases, the best move is to have the release out early, the executive free for calls in the hour after and the reporter briefed under embargo if you have a relationship that allows it.

For private companies, you have more room. An exclusive can work well for a meaningful financing or a launch out of stealth. Offering one outlet the story first, with a clear embargo time, gives the reporter a reason to invest in it. Be honest about the terms. Do not offer the same exclusive to two outlets, and do not let the story leak through another channel before the embargo lifts. Trade reporters remember who burned them.

Avoid launching modest news during the major conference weeks unless the news is being presented there. The days before and after a big oncology or hematology meeting are full of data, and only the strongest results get attention. A quieter week can give a smaller story real room.

Prepare for the call before you send the email

A good pitch earns a phone call, and the call is where many companies lose the story. Before you send anything, make sure your spokesperson can answer the obvious follow-ups without checking notes. How does this compare with the leading rival program? What were the adverse events? How much cash do you have, and how long does it last? What would make you stop the program? A reporter who gets straight answers will write a fuller, fairer story. A reporter who hears “we can’t comment on that” to every second question will write a shorter one and lean on analysts for the rest.

Have the supporting material ready as well: the full data slide deck, a clean figure the reporter can describe, the trial’s registry number and a one-paragraph company background. Small details like a correct spelling of the drug’s code name and the exact wording of the primary endpoint save time on deadline and reduce the odds of a correction later.

What to do when the news is not big enough

Plenty of companies have nothing that clears the bar this quarter. That does not have to mean silence. Endpoints and its readers value informed perspective, and executives with deep experience in a modality, a regulatory pathway or the financing market can become useful sources when reporters need context on someone else’s news.

Make that easy. Send the reporter a short note introducing your executive as a source on a specific topic, with two or three sharp views they can stand behind on the record. When a rival’s trial fails or a regulator makes a surprising call, a quick, candid comment from someone who knows the space is what a reporter on deadline needs.

Over time, that relationship makes your own news easier to pitch. A reporter who has quoted your CEO twice will open the email when your company has a readout of its own. That is the patient version of how to get featured in Endpoints News, and for many early-stage companies it is the one that works.

If you want a head start on the outlets and editors your story fits, our free journalist list for life sciences is a good place to begin. Whatever list you use, run the Readout Rule before you hit send.